# HM2014-26 DT2219 for Relapsed or Refractory B-Lineage Leukemia or Lymphoma

> **NCT02370160** · PHASE1,PHASE2 · COMPLETED · sponsor: **Masonic Cancer Center, University of Minnesota** · enrollment: 18 (actual)

## Conditions studied

- Refractory B-Lineage Leukemia
- Relapsed B-Lineage Leukemia
- Refractory B-Lineage Lymphoma
- Relapsed B-Lineage Lymphoma

## Interventions

- **BIOLOGICAL:** DT2219ARL

## Key facts

- **NCT ID:** NCT02370160
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-21
- **Primary completion:** 2018-04-08
- **Final completion:** 2018-04-08
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2020-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02370160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02370160, "HM2014-26 DT2219 for Relapsed or Refractory B-Lineage Leukemia or Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02370160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*